rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SNY
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      US FDA approves Sanofi's genetic disorder drug
      6h agoReutersSNY
      Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
      Nov 17Yahoo FinanceNVAXSNY
      Sanofi at Jefferies Global Healthcare Conference: vaccines reset gains pace
      Nov 17Investing.comSNYJEF
      Seawolf Therapeutics and Sanofi agree $1.2bn drug deal
      Nov 17Yahoo FinanceSNY
      Sanofi and the pan-Canadian Pharmaceutical Alliance sign Letter of Intent for Sarclisa®(isatuximab), a step toward public access for newly diagnosed, transplant-ineligible multiple myeloma patients

      Sanofi today announced the successful completion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), marked by a signed Letter of Intent (LOI) for Sarclisa® (isatuximab) intravenous (IV) in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the first-line treatment of adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).

      Nov 16Yahoo FinanceSNY
      DNA drug developer Seawolf launches with $100 million funding, Sanofi deal
      Nov 16ReutersCRSPSNY
      Why Is Sanofi (ENXTPA:SAN) Expanding Its R And D Bets In Vaccines And Gene Editing?
      Nov 13Yahoo FinanceSNY
      Sanofi: Information concerning the total number of voting rights and shares - October 2026
      Nov 12Yahoo FinanceSNY
      Sanofi (SNY) Is Planning for a Patent Loss, Here’s Where Bulls Still See Opportunity
      Nov 10Yahoo FinanceSNY
      NVAX Q3 2026 deep dive: Sanofi milestone and cost controls shape outlook

      Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales fell by 3% year on year to $68.3 million. The company’s full-year revenue guidance of $400 million at the midpoint came in 4.2% above analysts’ estimates. Its non-GAAP loss of $0.19 per share was 54.8% above analysts’ consensus estimates.

      Nov 10Yahoo FinanceSNY
      Sodium valproate documentary airs as Bognor Regis mum tells story

      Janet Stockley-Pollard's children are among those living with the effects of sodium valproate use.

      Nov 10BBCSNY
      Novavax Inc (NVAX) (Q3 2026) Earnings Call Highlights: Sanofi Milestone Lifts Revenue Outlook ...
      Nov 6Yahoo FinanceNVAXSNY
      Sanofi Stock And Why Earnings Guidance Raised Matters For Shareholders
      Nov 5Yahoo FinanceSNY
      Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Sanofi (OtherSNYNF)

      Tipranks Press Release.

      Nov 5The Globe and MailBNTXSNY
      NVAX Q3 2026 deep dive: Sanofi milestone and cost controls shape outlook

      Detailed price information for Novavax Inc (NVAX-Q) from The Globe and Mail including charting and trades.

      Nov 5The Globe and MailNVAXSNY
      Sanofi (ENXTPA:SAN) Stock Looks Discounted Despite Its 20% Monthly Run
      Nov 5Yahoo FinanceSNY
      NRIX Stock Clocks Worst Day Ever After Sanofi Discontinues Trial Of Licensed Drug: Wells Fargo Slashes Price Target
      Nov 4Yahoo FinanceSNYWFC
      Sanofi stops development of Nurix-partnered immune drug
      Nov 4Yahoo FinanceSNY
      CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation Index
      Nov 4Yahoo FinanceSNY
      Sanofi Breaks Out; Why Its Eczema Partner Just Crashed

      Its partner is a highly rated biotech stock that was forming a consolidation ahead of the news.

      Nov 4Investor's Business DailyNRIXSNY
      Nurix Therapeutics Shares Plunge 28.4% as Sanofi Terminates STAT6 Drug Development Programme
      Nov 4Yahoo FinanceNRIXSNY
      Nurix stock falls as Sanofi scraps partnered drug (NRIX:NASDAQ)
      Nov 4Seeking AlphaNRIXSNY
      Nurix Therapeutics stock tumbles on Sanofi program termination

      Investing.com -- Nurix Therapeutics Inc. (NASDAQ:NRIX) shares fell 34% in after-hours trading Tuesday following Sanofi’s decision to discontinue development of SAR448272, an oral STAT6 degrader.

      Nov 3Yahoo FinanceSNY
      Nurix says Sanofi discontinues autoimmune disease drug program
      Nov 3ReutersNRIXSNY
      Sanofi discontinues Nurix drug trial, terminates program
      Nov 3Investing.comNRIXSNY
      Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272
      Nov 3Yahoo FinanceNRIXSNY
      Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues
      Nov 3Yahoo FinanceSNY
      Sanofi (SNY) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 2The Globe and MailSNY
      Sanofi (ENXTPA:SAN) Stock Can Q3 Earnings Sustain Its Revenue Strength
      Nov 1Yahoo FinanceSNY
      Regeneron Q3 2026 slides: record results, $8B Sanofi alliance
      Nov 1Investing.comREGNSNY
      Earnings call transcript: Sanofi tops Q3 2026 forecasts and lifts guidance
      Nov 1Investing.comSNY
      Sanofi SA (SNY) (Q3 2026) Earnings Call Highlights: Dupixent Tops EUR5 Billion Again as ...

      Sanofi SA (SNY) raised its 2026 outlook to low-teens sales growth and mid-teens business EPS growth after Q3 sales rose 14.3% to EUR14.4 billion, led by Dupixent and a new launch portfolio up 19.2%.

      Oct 30Yahoo FinanceSNY
      Sanofi Jumps 6% as New CEO Opens Door to Bigger Deals
      Oct 30Yahoo FinanceSNY
      Regeneron (REGN) stock trades up, here is why

      Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

      Oct 30The Globe and MailREGNSNY
      Sanofi Q3 Earnings Call Highlights
      Oct 30Yahoo FinanceSNY
      Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It
      Oct 30BenzingaSNY
      Sanofi Raises Profit Forecast on Blockbuster Dupixent Sales
      Oct 30BloombergSNY
      Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts

      Regeneron stock popped Thursday after its Sanofi-partnered allergic conditions drug, Dupixent, easily beat sales calls.

      Oct 30Investor's Business DailyREGNSNY
      Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise
      Oct 30Yahoo FinanceSNY
      Regeneron stock gains on Q3 beat (REGN:NASDAQ)

      Regeneron Pharmaceuticals (REGN) stock rises as the company posts higher-than-expected Q3 2026 results thanks to its Sanofi (SNY) collaboration. Read more here.

      Oct 30Seeking AlphaREGNSNY
      Regeneron Q3 revenue tops estimates on Sanofi Dupixent profit; shares rise 4%
      Oct 30Investing.comREGNSNY
      Sanofi CEO Sets Sights on Deals to Drive Turnaround

      The French drugmaker is moving to fill its medicine pipeline to prepare for the looming patent expiration of its bestselling product, Dupixent.

      Oct 30WSJSNY
      Sanofi weighs M&A opportunities to replenish pipeline, lifts 2026 growth targets By Reuters
      Oct 30Investing.comSNY
      Sanofi weighs M&A opportunities to replenish pipeline, lifts 2026 growth targets

      By Bhanvi Satija LONDON, Oct 30 (Reuters) - French drugmaker Sanofi said on Friday that dealmaking will be an important part of replenishing the company's drug pipeline under new CEO Belen Garijo,

      Oct 30Yahoo FinanceSNY
      Why is Sanofi stock surging today?
      Oct 30Investing.comSNY
      Sanofi lifts profit outlook on strong Dupixent sales (SNY:NASDAQ)

      Sanofi lifts 2026 guidance after a strong Q3 earnings beat, fueled by Dupixent and new drug launches.

      Oct 30Seeking AlphaSNY
      Sanofi Q3 earnings blow past expectations on Dupixent strength; hikes FY guidance
      Oct 30Yahoo FinanceSNY
      Sanofi ADR earnings beat by $2.46, revenue topped estimates
      Oct 30Investing.comSNY
      Sanofi lifts expectations for 2026 sales growth, looks to M&A
      Oct 30Yahoo FinanceSNY
      Novavax earns $125M milestone from Sanofi vaccine trial
      Oct 29Investing.comNVAXSNY

      This is the newest page. Registered accounts read further back.